How do you sequence treatment for patients with HER2-mutant metastatic NSCLC?

It is a challenge that we should face with great excitement, as HER2 in lung cancer, up until recently, was EGFR’s poor sibling, as so astutely highlighted by Dr. Carbone in his recent NEJM editorial. Indeed, while we have seen dramatic changes with generations of EGFR TKIs and now combinations, suc...